Abstract
The process of B-cell development is characterized by the activation of the unfolded protein response. Under certain circumstances, the unfolded protein response can be manipulated in a cell death-inducing way. Therefore, tackling the unfolded protein response might be an attractive strategy in the treatment of diffuse large B-cell lymphomas. Our research showed more basal unfolded protein response activity and differences in the inducibility of ER stress in activated B-cell versus germinal center cell lines. Moreover, the diffuse large B cell lymphoma patient data revealed that the glucose-regulated protein 94 is new potential discriminator for diffuse large B cell lymphoma.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Apoptosis
-
Biomarkers, Tumor / metabolism
-
Cell Line, Tumor
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Endoplasmic Reticulum Stress*
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / metabolism*
-
Lymphoma, Large B-Cell, Diffuse / pathology*
-
Membrane Glycoproteins / analysis
-
Membrane Glycoproteins / physiology*
-
Prednisone / administration & dosage
-
Unfolded Protein Response*
-
Vincristine / administration & dosage
Substances
-
Biomarkers, Tumor
-
Membrane Glycoproteins
-
endoplasmin
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone